Clinical Trial Update: BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica [Phase 2]

View source ↗

Summary

Phase 2 trial update for bari-citinib in polymyalgia rheumatica has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polymyalgia Rheumatic
• Polymyalgia Rheumatica

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: University Hospital, Brest | Conditions: Polymyalgia Rheumatic (PMR) | Phase 2 | Status: COMPLETED